Tyrosine Kinase Inhibitor

9 Drugs classified under this drug class

Tyrosine Kinase Inhibitor. Dasatinib 20, 50, 70, 100 mg.
FC Tabs: 60X 20, 50, 70mg,30X 100 mg. Recomm. starting dose for chron. phase CML is 100 mg dasatinib/d. Recomm. starting dose for accel., myeloid or lymphoid blast phase (adv. phase) CML or Ph+ ALL is 140 mg/d. Tmt. until dis. progress. or until no longer toler. by ptt. Dose incr. or reduct. based on ptt. resp. and tolerab.
Tmt. of adlt pts. with:
• Newly diagn. Philadelphia chrom. positive(Ph+ )
chronic myelogen. leukaemia (CML) in the chron. phase.
• Chronic, acceler. or blast phase CML with
resist. or intoler. to prior ther. incl. imatinib mesilate.
• Ph+ ac. lymphoblastic leukaemia(ALL) and lymphoid blast CML with resist. or intoler. to prior ther.
C/I:Hypersens.

Tyrosine Kinase Inhibitor. Erlotinib 100 mg, 150 mg.
TABS: 30 x 100 mg, 150 mg. Non-small
cell lung cancer: 150 mg 1 x dly
without food. Pancreat. cancer: 100 mg
dly without food in comb. with
gemcitabine.
First-line tmt. locally advanced/metastat.
non-small cell lung cancer (NSCLC) with
EGFR activat. mutats. Tmt. locally.
advanced/metastat. NSCLC aft. fail. of at
least one prior chemother. reg. Monother.
for maint. tmt. pts with locally advanc./
metastat. non-small cell lung cancer
whose disease not progress. aft. 4 cycles of
platinum-based first-line chemother. In
comb. with gemcitabine for first-line tmt.
with locally advanced, unresect./
metastat. pancreat. cancer.
C/I: Hypersens.

Tyrosine Kinase Inhibitor. Imatinib 100 mg, 400 mg.
F.C. TABS: 20, 60 x 100 mg; 10, 30 x
400mg.
Doses of 400 mg or 600 mg should be
admin. once dly., whereas a daily dose
of 800 mg should be admin. as 400 mg
×2/d in the morn. and even.
Tmt. of adult pts. and child. 3 yrs. of age
and above with Ph+ chron. myeloid
leukaemia (Ph+ -CML) in chron. phase
accelerat. phase or blast crisis. Glivec is
also indicat. for the tmt. of adult pts.s
with Kit (CD117) posit. unresect. and/or
metastat. malignant GI strom. tumour.
(GIST). Also indicated for the tmt. of :
Adult pts. with newly diagnosed
Philadelphia chromos. posit. acute
lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy. Adult pts.
with relapsed or refract. Ph + ALL as
monother. Adult pts. with unresect.
dermatofibrosarcoma protuberans
(DFSP) and adult pts. with recurrent and/
or metastat. DFSP who are not eligible
for surg. Adult pts. with myelodyspiastic/
myeloproliferative dis.(MDS/MPD) assoc.
with PDGFR ( platelet - derived growth
factor recept. ) gene re- arrangements.
Adult pts. with hypereosinophilic syndr.
(HES) and/or chronic eosinophilic
leukaemia (CEL) who have the FIP1L1-
PDGFRalfa fusion kinase (mutational
analysis or FISH demonstration fo CHIC2
allele deletion) and for pts. with HES and/
or CEL who are FIP1L1-PDGFR alfa fusion
kinase negative . Adult pts. with aggress.
systemic mastocytosis (ASM) without the
D816V c-kit mutation .Adjuvant tmt. of
adult pts. follow. complete gross resec. of
Kit (CD117) positive GIST.
C/I: Hypersens.

Tyrosine Kinase Inhibitor. Axitinib 1 mg, 5 mg.
F.C. TAB: 28, 56, 60, 180 × 5, 1 mg.
Recomm. init. oral dose is 5 mg×2/d. approx. 12 hrs. apart with/without food. Should be swallow. whole with a glass of water. If the pt. vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time. See lit.
Tmt. of advanc. RCC after fail. of one prior syst. therapy.
C/I: Hypersens.

Tyrosine Kinase Inhibitor. Ruxolitinib Phosphate 5 mg, 10 mg, 15 mg, 20 mg.
TAB: blist.: 56, bottle.: 60×5, 15, 20mg
Start. dose:
MF: The recomm. start. dose: in is 15
mg ×2/d for pts. with a plat. count
between 100,000/mm³ and 200,000/
mm 3 and 20 mg ×2/d for pts. with a
plat. count of >200,000/mm³.
PV: The recomm. start. dose of is 10
mg×2/d.
Limited inform. to recommend a start.
dose for pts. with plat. count. between
50,000/mm³ & <100,000/mm³.
The max. recomm. start. dose in these
pts. is 5 mg ×2/d and the pts. should be
titrated cautious.
Dose modific.: Doses may be titrat. based on safety & efficacy. Tmt. should be discont. for plat. counts less than 50,000/mm³ or absolute neutrophil counts less than 500/mm³. In PV, tmt. should also be interrupt. when haemoglobin is below
8 g/dl. After recov. of blood count. above these levels, dosing may be re-started at 5 mg ×2/d and gradual. incr. based on careful. See. lit.
Myelofibrosis (MF).: Tmt. of dis.-related splenomeg.or sympt. in adult pts. with prim. MF (also known as chron. idiopath. MF), post polycythaem. vera myelofibrosis or post essential thrombocythaem. MF.
Polycythaem. vera (PV).: Tmt. of adult pts. with PV who are resist. to or intolerant of hydroxyurea.
C/I: Hypersens. Preg. Lact.

ALK, Tyrosine Kinase Inhibitor. Lorlatinib 25 mg, 100 mg.
F.C. TABS.: 90, 120×25mg, 30×100mg. 100 mg×1/day orally, with/without food, at the same time each day, until dis. progress. or unacceptab. toxic.
Swallow tablets whole. If a dose is missed, then the missed dose should be taken, unless the next dose is due within 4 hrs. If vomit. occurs after lorlatinib cont. with the next scheduled dose. 2 doses should not be taken at the same time to make up for a missed dose. See lit.
Tmt. of adult pts. with metast. NSCLC whose tumors are anaplast. lymphom. kinase (ALK)-positive.
C/I: Pts. taking strong CYP3A induc., due to the potential for serious hepatotox. Hypers.